Stocks
Rapid risers (past year)
AMD · Advanced Micro Devices IncBuya year ago$107.68→now$507.29+371%market value$827.2BMakes computer chips used in PCs, gaming consoles, and data centers.
why The headlines do not clearly explain AMD's 371% rise — they reference a Rackspace deal with AMD and general market dips, but none of the provided headlines substantively explain the massive year-long gain. source
Analysts are broadly bullish — the explosive run has cemented AMD as a top semiconductor pick.
GOOGL · Alphabet IncBuya year ago$176.51→now$373.25+112%market value$4.52TRuns the world's dominant search engine and a major cloud computing business.
why The headlines do not clearly explain GOOGL's 111.5% rise — the most relevant headline mentions HSBC partnering with Google Cloud to expand AI usage, suggesting AI cloud momentum, but the provided sources are insufficient to fully explain the move. source
Overwhelming buy consensus — analysts see AI-driven advertising and cloud growth as a powerful combo.
AVGO · Broadcom IncBuya year ago$237.82→now$376.71+58%market value$1.79TDesigns and sells semiconductor chips and software used in networking and data centers.
why The headlines do not clearly explain AVGO's 58.4% rise — the sources mention Broadcom leading a Nasdaq drop and analyst top picks but do not provide a substantive explanation for its year-long gain. source
Strong buy sentiment — analysts love its AI infrastructure exposure and steady cash flows.
AAPL · Apple IncBuya year ago$198.32→now$299.24+51%market value$4.40TMakes iPhones, Macs, and related software and services.
why The headlines do not clearly explain AAPL's 50.9% rise — the most relevant headline mentions Apple facing an Italy DMA probe over cloud interoperability, which is a headwind, and no provided headline explains the year-long gain.
Analysts lean bullish — momentum is back, though the premium valuation keeps some on the sidelines.
JNJ · Johnson & JohnsonBuya year ago$156.78→now$235.18+50%market value$566.1BDevelops and sells prescription medicines, medical devices, and consumer health products.
why Johnson & Johnson's CEO publicly stated that curing certain cancers within a decade is realistic and the company dropped key cancer trial results, suggesting strong oncology pipeline optimism that likely supported the stock's rise. source
Majority buy — seen as a steady, defensive compounder with solid pipeline optionality.
NVDA · NVIDIA CorpBuya year ago$138.60→now$207.41+50%market value$5.02TMakes graphics processors and AI computing chips widely used in data centers and gaming.
why The provided headlines do not explain NVDA's 49.6% gain — none of the listed headlines directly discuss Nvidia's business performance or drivers of its stock price over the past year.
Near-unanimous buy — analysts view it as the defining infrastructure play of the AI era.
LLY · Eli Lilly and CoBuya year ago$814.39→now$1,122.50+38%market value$1.06TDevelops and sells pharmaceutical drugs, including blockbuster weight-loss and diabetes treatments.
why Eli Lilly's stock likely rose due to its leading position in the fast-growing GLP-1 receptor agonist and obesity drug market, with headlines highlighting its potential next-generation weight-loss drug retatrutide and competition with Novo Nordisk. source
Strong buy chorus — analysts expect its obesity drug franchise to drive growth for years.
MRK · Merck & Co IncBuya year ago$81.90→now$115.17+41%market value$284.4BResearches and sells prescription medicines, vaccines, and animal health products.
why The provided headlines do not clearly explain MRK's 40.6% rise — the most relevant headlines reference minor collaborations and investments alongside Merck but do not substantively explain the year-long stock gain.
Mostly bullish — analysts see durable revenue from its cancer drug Keytruda as a key anchor.
UNH · UnitedHealth Group IncBuya year ago$310.94→now$407.65+31%market value$360.1BProvides health insurance plans and healthcare services across the United States.
why The provided headlines do not clearly explain UNH's 31.1% rise — one headline asks why UnitedHealth chose 'pain over growth,' suggesting the stock's performance was debated, but no headline clearly explains the year-long gain.
Broad buy consensus — analysts view its scale and diversified model as hard to beat in healthcare.
ABBV · AbbVie IncBuya year ago$191.84→now$222.47+16%market value$393.1BDevelops and sells specialty medicines, including treatments for immune conditions and cancer.
why AbbVie's stock rose modestly, supported by a label expansion that maintained a Strong Buy analyst rating and a headline claiming a $15 billion operational beat that rewrote the bear thesis against the company. source
Solid buy rating — analysts are encouraged by its post-Humira pipeline holding up well.
Decliners (past year)
COIN · Coinbase Global IncBuya year ago$242.21→now$169.27-30%market value$44.6BOperates a platform where people can buy, sell, and store cryptocurrencies.
why The provided headlines are mostly positive or neutral (tokenized stocks launch, Ethereum price jump) and do not explain a 30% decline in Coinbase's stock over the past year.
Still a net buy from analysts, but the sharp decline reflects how volatile crypto sentiment can be.
MSFT · Microsoft CorpBuya year ago$467.91→now$393.83-16%market value$2.93TSells cloud computing services, productivity software, and operating systems worldwide.
why Microsoft closed Xbox studios and weighed a spin-off, signaling strategic restructuring that may have weighed on investor sentiment. source
Analysts remain overwhelmingly bullish despite the pullback — many see it as a long-term AI winner at a better price.
META · Meta Platforms IncBuya year ago$690.61→now$600.21-13%market value$1.52TOperates Facebook, Instagram, and WhatsApp, earning most revenue from digital advertising.
why The provided headlines are broadly positive (Threads reaching 500 million monthly users) and do not explain a 13% decline in Meta's stock over the past year.
Strong buy consensus — analysts think the dip overstates risks and that ad revenue remains resilient.
ORCL · Oracle CorpBuya year ago$210.40→now$188.33-10%market value$541.6BSells database software and cloud services to businesses around the world.
why The provided headlines do not clearly explain a 10.5% decline; while one headline notes a report of a failed Microsoft cloud deal (which Oracle disputed), the sources are insufficient to fully attribute the move. source
Mostly bullish — analysts are encouraged by its cloud momentum even after a rough year overall.
BRK.B · Berkshire Hathaway IncSella year ago$487.73→now$494.95+2%market value$1.07TOwns a large collection of businesses and stock investments managed by Warren Buffett.
why The provided headlines do not explain the modest 1.5% gain in Berkshire Hathaway stock over the past year; the sources discuss broader market themes and comparisons to other companies but offer no direct explanation.
Rare sell-leaning consensus — analysts are cautious, seeing limited upside relative to the broader market.
PFE · Pfizer IncHolda year ago$24.58→now$26.04+6%market value$148.4BDiscovers, manufactures, and sells prescription medicines and vaccines globally.
why The provided headlines do not clearly explain a 5.9% rise in Pfizer's stock; the most relevant headline notes Rigel closing a licensing agreement involving Pfizer's VEPPANU asset, generating an upfront payment, but the sources are insufficient to fully attribute the annual move. source
Consensus sits at hold — analysts are waiting to see if its post-pandemic pipeline can pick up the slack.
Potential (room to grow)
QCOM · Qualcomm IncHold3 months ago$125.86→now$214.07+70%market value$225.6BMakes the chips that power smartphones, cars, and connected devices around the world.
why Qualcomm stock likely rose as the CEO unveiled a bold AI wearables push and plans to leverage AI in new ways, generating investor excitement about growth opportunities beyond smartphones. source
It has been one of the strongest recent performers, beating the broader market by a wide margin over the past three months, and analysts are broadly neutral to positive, reflecting its solid footing.
- UNH · UnitedHealth Group IncBuy3 months ago$279.76→now$407.65+46%market value$360.1B
Runs one of the largest health insurance and healthcare services networks in the United States.
why The headlines do not clearly explain a 31% rise in UnitedHealth stock; one headline asks 'Why Did UnitedHealth Stock Choose Pain Over Growth?' suggesting the move may have been complex or mixed, and the sources do not provide a clear positive catalyst.
It has surged well ahead of the market over the past three months and carries strong buy support from analysts, suggesting continued confidence in its growth outlook.
GE · General Electric CoBuy3 months ago$307.98→now$351.73+14%market value$367.0BBuilds jet engines and aviation systems used by airlines and defense customers globally.
why GE Aerospace stock rose strongly as the company outperformed the broader market, driven by strong aerospace demand and positive momentum including a breakout highlighted by analysts. source
It has delivered impressive gains over the past year and outpaced the broader market in the last three months, backed by a heavily buy-weighted analyst consensus.
BA · Boeing CoBuy3 months ago$208.55→now$227.49+9%market value$179.3BDesigns and manufactures commercial airplanes and defense aircraft for customers worldwide.
why Boeing stock posted a modest gain despite ongoing scrutiny following a B-52 crash and continued operational challenges, and the headlines do not point to a clear positive driver for the 14% rise.
It has outperformed the market noticeably over the past three months and analysts are overwhelmingly in the buy camp, pointing to a recovery story with real momentum.
- ABBV · AbbVie IncBuy3 months ago$220.55→now$222.47+1%market value$393.1B
Develops and sells medicines, including treatments for immune conditions and cancer.
why AbbVie stock rose as the company beat operational expectations by $15 billion, rewriting the bear thesis, and received a label expansion that supported analysts maintaining a strong buy rating. source
It has edged ahead of the market over three months while posting solid year-on-year gains, and analysts are strongly in favor with no sell ratings, suggesting steady growth confidence.
TMO · Thermo Fisher Scientific IncBuy3 months ago$463.30→now$472.63+2%market value$175.6BSupplies scientific instruments, lab equipment, and services to researchers and drug makers.
why The available headlines do not explain Thermo Fisher's 17.6% rise; coverage initiations were neutral and headlines are largely about competitors or tangential topics.
It has outpaced the market over the past three months and enjoys one of the cleanest analyst scorecards in the dataset, with buys far outweighing any negative views.
- MRK · Merck & Co IncBuy3 months ago$115.88→now$115.17-1%market value$284.4B
Researches and sells prescription medicines and vaccines for a wide range of diseases.
why The headlines do not clearly explain Merck's 40.6% rise; the sources reference collaborations and investments alongside Merck but do not identify a specific major catalyst for such a large gain.
Strong year-on-year gains combined with outperforming the market over three months, plus a buy-heavy analyst consensus with zero sell ratings, make it a compelling growth candidate.
ABNB · Airbnb IncBuy3 months ago$128.34→now$141.20+10%market value$85.1BRuns an online platform where people can list or book short-term home rentals and experiences.
why The available headlines do not clearly explain Airbnb's near-flat 2.5% move; the sources include a competitor assessment and a brief note on the stock trading up, but no specific major catalyst is identified.
It has outperformed the broader market over the past three months and holds a buy-leaning analyst consensus, suggesting growing confidence in travel demand and its business model.
SHOP · Shopify IncBuy3 months ago$123.77→now$113.23-8%market value$146.9BProvides software and tools that help businesses of all sizes sell products online and in stores.
why The available headlines do not clearly explain Shopify's modest 6.8% gain; headlines discuss AI retail infrastructure potential and analyst disagreements on the stock but no single dominant catalyst is identified.
Analysts are overwhelmingly bullish with almost no sell ratings, and while it has faced recent pressure it has held up better than many peers, leaving room for a rebound.
UBER · Uber Technologies IncBuy3 months ago$73.73→now$73.25-1%market value$140.2BOperates a global app for ride-hailing, food delivery, and freight logistics.
why Uber stock likely fell as it faces growing competitive threats entering the autonomous vehicle era, with questions raised about its long-term positioning against both Lyft and self-driving technology disruption. source
It has nearly matched the market over three months while carrying the largest concentration of buy ratings in the entire dataset, reflecting very high analyst conviction in its growth path.
COST · Costco Wholesale CorpBuy3 months ago$1,015.87→now$986.68-3%market value$437.6BRuns a chain of membership warehouse clubs where shoppers buy everyday goods in bulk at low prices.
why The available headlines do not clearly explain Costco's near-flat -1.1% move; headlines note growing traffic and a strong value strategy but these would suggest a positive return, not a slight decline.
It has significantly outperformed the broader market over three months with much smaller losses, and a strong buy consensus points to its resilience and steady growth appeal.
HD · Home Depot IncBuy3 months ago$346.50→now$337.09-3%market value$336.1BOperates a large chain of home improvement stores selling tools, materials, and appliances.
why Home Depot stock likely fell due to a weakening housing market, with one headline explicitly warning that housing is 'toast' in 2026, which would dampen demand for home improvement spending. source
It has held up far better than the market over the past three months and benefits from a buy-tilted analyst base, with almost no negative ratings, suggesting durable long-term potential.
PLTR · Palantir Technologies IncBuy3 months ago$149.31→now$133.25-11%market value$319.4BBuilds data analytics and artificial intelligence software used by governments and large companies.
why Palantir stock likely fell as the company faced legal losses in Switzerland, contract exits in France, and scrutiny over its NHS contract in the UK, weighing on its European growth prospects. source
It has meaningfully outperformed the market over the past three months and carries a buy consensus from analysts, reflecting strong belief in its AI-driven growth story.
DIS · Walt Disney CoBuy3 months ago$98.89→now$101.28+2%market value$175.9BCreates and distributes entertainment through theme parks, movies, TV channels, and streaming.
why The available headlines do not clearly explain Disney's -13.8% decline; the sources largely discuss Netflix and IMAX rather than specific negative catalysts for Disney over the past year.
It has edged above the market over the past three months with positive performance, and an overwhelmingly buy-rated analyst view suggests the market sees a genuine recovery ahead.
Not generated yet.